Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$6.85 USD
+0.44 (6.86%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.86 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Mesoblast Limited [MESO]
Reports for Purchase
Showing records 1 - 20 ( 91 total )
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Halted Capital Raise? Lowering to Neutral. Let?s Face it Regenerative Medicine Effect Size is Modest at Best
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Rexlemestrocel -L Shows Improvement in Ejection Fraction, The Data is Encouraging but It?s a Long Road Ahead; We Are Lowering Our Price Target from $12.0 to $7.0
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BLA Resubmission on the Horizon; Cutting Costs to Extend Runway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Reports the Quarter - Spending Reduced to $15M, $77M in Cash on Hand - Remestemcel-L Resubmission in the Works
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Reports the Quarter - Spending Reduced to $15M, $77M in Cash on Hand
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Reports Results - We are Lowering Our Price Target to $12 from $16 Based on Anticipated Future Dilution
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Major Regulatory Milestones Anticipated in 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Remestemcel-L Shows Utility in Crohn''s
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Quarter Update Remestemcel-L; One Step Closer
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Building on the Foundations of Treatment: Advances in Heart Failure Therapy
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Saving Children?s Lives - Remestemel-L
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Reports YE (June 2021) Approaching an Inflection Point
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Multiple Upcoming Regulatory Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Closing in on GvHD, COVID, DDD and CHF
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J